Stay updated on Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial
Sign up to get notified when there's something new on the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page.

Latest updates to the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page
- Check4 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision: v3.4.2 is now displayed, and the previous maintenance notice (Revision: v3.4.1) was removed.SummaryDifference0.4%

- Check39 days agoChange DetectedA site-wide notice about a lapse in government funding was added, and the page now shows Revision: v3.4.1 (replacing v3.4.0).SummaryDifference0.4%

- Check46 days agoChange DetectedThe changes are cosmetic/UI and metadata updates: the glossary toggle is shown, the capitalization of 'Met QC Criteria' is adjusted, the No FEAR Act data label is updated, and the revision/version is updated to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing the previous Revision: v3.3.3.SummaryDifference0.0%

- Check82 days agoChange DetectedA new Locations section was added listing study sites in Minnesota, New Jersey, New York, Pennsylvania, and Utah, and state-specific location subsections were removed. The page revision updated to v3.3.3.SummaryDifference0.6%

Stay in the know with updates to Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page.